Startup | September 17, 2025
Bayer launches biotech innovation platform in China
Bayer Co.Lab AdVenture platform will accelerate biotech innovation through global investment networks
Bayer Co.Lab AdVenture platform will accelerate biotech innovation through global investment networks
This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis
Accro will retain global rights to develop, manufacture, and commercialize AC-201 (excluding Chinese Mainland, Hong Kong SAR, and Macau SAR)
SUP will obtain regulatory approvals for selling Tiotropium DPI in China
Record international participation reflects renewed momentum in pharma manufacturing and global sourcing, as easing tariffs fuel growth
3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8 billion
This approval authorizes the company to export Ibuprofen to the Chinese markets
This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally
Subscribe To Our Newsletter & Stay Updated
